Cancer Biopsy Market Forecast Analysis Through 2030 With Insights On Industry Expansion

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Cancer Biopsy Market Over The Forecast Period?

The cancer cachexia market has demonstrated significant expansion in recent years. Its value is expected to rise from $2.6 billion in 2025 to $2.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to factors such as a greater occurrence of late-stage cancer diagnoses, improved clinical understanding of cachexia management, increasing distribution via hospital pharmacies, the initial adoption of anabolic agents, and the wider availability of supportive oncology care.

The cancer cachexia market size is projected to experience robust expansion over the coming years. By 2030, this market is predicted to reach $3.35 billion, demonstrating a compound annual growth rate (CAGR) of 5.1%. Several factors contribute to this projected growth, including a surge in demand for tailored cachexia therapies, advancements in clinical research exploring new mechanisms, the widening availability of outpatient oncology services, the increasing adoption of digital tools for patient monitoring, and a greater emphasis on improving quality-of-life outcomes. Key trends anticipated during this period encompass the increased application of combination drug regimens, a heightened focus on therapies aimed at muscle preservation, the broader acceptance of nutritional supplementation approaches, the expansion of anti-inflammatory treatments for cachexia, and more sophisticated monitoring of cachexia progression.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19355&type=smp

Which Growth Factors Are Strengthening The Cancer Biopsy Market Landscape?

The rising incidence of cancer is projected to stimulate the expansion of the cancer cachexia market moving forward. Cancer is defined as a condition where abnormal cells multiply without control in the body, forming tumors and disrupting normal bodily functions. The incidence of cancer is attributed to various factors, including evolving lifestyles, environmental influences, an aging demographic, genetic predisposition, enhanced diagnostic methods leading to earlier detection, and increased awareness, prompting more individuals to seek medical attention. Advances in medical technology and an improved understanding of cancer and its complications are leading to more frequent diagnoses and reporting of cancer cachexia. Healthcare professionals are enhancing their capacity to identify cachexia symptoms, thereby facilitating earlier interventions and the commencement of treatment. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the increasing prevalence of cancer is propelling the growth of the cancer cachexia market.

Which Segment-Based Categories Are Covered In The Cancer Biopsy Market?

The cancer biopsy market covered in this report is segmented –

1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types

2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications

3) By End User: Hospitals, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies

2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing

3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies

Which Trends Are Supporting The Evolution Of The Cancer Biopsy Market?

Leading companies in the cancer cachexia market are developing innovative medications, such as monoclonal antibodies for cachexia, to create targeted treatments for cancer cachexia, aiming to enhance body weight, muscle mass, and the overall quality of life for affected patients. A monoclonal antibody for cachexia works by targeting and inhibiting factors that cause muscle and weight loss. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical company, announced the positive results from its Phase 2 study for Ponsegromab, a monoclonal antibody targeting GDF-15, in patients with cancer cachexia. This study demonstrated a significant increase in body weight and improvements in muscle mass, appetite, and physical activity, with the 400 mg dose exhibiting the most robust results. Building on these promising findings, Pfizer plans to initiate registration-enabling studies in 2025 to further explore Ponsegromab’s potential in treating cancer cachexia.

Who Are The Businesses Driving Activity In The Cancer Biopsy Market?

Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc

Access The Complete Cancer Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biopsy-global-market-report

Which Region Is The Primary Market For The Cancer Biopsy Market?

North America was the largest region in the cancer biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Biopsy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=19355&type=smp

Browse Through More Reports Similar to the Global Cancer Biopsy Market 2026, By The Business Research Company

Anorectal Disorders Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report

Oncology Nutrition Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report

Progressive Ataxia And Weakness Disorders Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795